List of Neuraceq drug patents
Neuraceq is owned by Life Molecular.
Neuraceq contains Florbetaben F-18.
Neuraceq has a total of 1 drug patent out of which 0 drug patents have expired.
Neuraceq was authorised for market use on 19 March, 2014.
Neuraceq is available in solution;intravenous dosage forms.
Neuraceq can be used as neuraceq is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate p-amyloid neuritic plaque density in adult patients with cognitive impairment.
The generics of Neuraceq are possible to be released after 18 March, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7807135 | LIFE MOLECULAR | Stilbene derivatives and their use for binding and imaging amyloid plaques |
Mar, 2029
(5 years from now) | |
Drugs and Companies using FLORBETABEN F-18 ingredient
Market Authorisation Date: 19 March, 2014
Treatment: Neuraceq is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate p-amyloid neuritic plaque density in adult patients with cognitive impairment
Dosage: SOLUTION;INTRAVENOUS
NEURACEQ family patents
7
United States
3
European Union
2
Israel
1
Portugal
1
Singapore
1
Spain
1
Brazil
1
Costa Rica
1
New Zealand
1
Norway
1
Mexico
1
China
1
Korea, Republic of
1
EA
1
South Africa
1
Lithuania
1
Canada
1
Japan
1
Luxembourg
1
Slovenia
1
Hungary
1
Ukraine
1
Poland
1
Australia
1
Denmark
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic